Bizarre Patents
Apparatus for Simulating a High Five
A self-righting hand-arm configuration which is adapted to pivot when struck by a user, thereby simulating a "high five."
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8124731 | Optimized Fc variants and methods for their generation The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants. ... | 02/28/2012 |
| 8101720 | Immunoglobulin insertions, deletions and substitutions An Fc variant of a parent Fc polypeptide, wherein said Fc variant exhibits altered binding to one or more FcγRs, wherein said Fc variant comprises at least one amino acid insertion in the Fc region of said parent Fc polypeptide. ... | 01/24/2012 |
| 8093359 | Optimized Fc variants and methods for their generation The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants. ... | 01/10/2012 |
| 8093357 | Optimized Fc variants and methods for their generation The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants. ... | 01/10/2012 |
| 8088376 | Fc variants with altered binding to FcRn The present application relates to a variant Fc region comprising the double mutation 428L/434S that increases serum half-life and the numbering is according to the EU index. ... | 01/03/2012 |
| 8084582 | Optimized anti-CD20 monoclonal antibodies having Fc variants The present invention relates to optimized CD20 antibodies having Fc variants, methods for their generation, and method for their application, such as methods of enhancing macrophage activation, particularly for therapeutic purposes. ... | 12/27/2011 |
| 8063187 | Methods and compositions for inhibiting CD32B expressing cells The present invention relates to immunoglobulins that bind FcγRIIb+ cells and coengage the antigen on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins. ... | 11/22/2011 |
| 8039592 | Optimized Fc variants and methods for their generation The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants. ... | 10/18/2011 |
| 7973136 | Optimized anti-CD30 antibodies An antibody that targets CD30, wherein the antibody comprises at least one modification relative to a parent antibody and the antibody binds with altered affinity to an FcgR or alters effector function as compared to the parent antibody. Also disclosed are methods o... | 07/05/2011 |
| 7930107 | Methods of generating variant proteins with increased host string content The present invention relates to novel methods for generating variant proteins with increased host string content, and proteins that are engineered using these methods. ... | 04/19/2011 |
| 7749956 | Method of treatment using adiponectin variants A method of treating a mammal with an adiponectin mediated disorder comprising administering a therapeutically effective amount of an adiponectin variant with at least a 3-fold increased solubility relative to residues 110-244 of human adiponectin. ... | 07/06/2010 |
| 7709607 | Adiponectin variants An adiponectin variant with one or more amino acid modifications relative to a corresponding parent adiponectin, wherein the solubility of the variant is improved by at least 3-fold relative to residues 110-244 of human adiponectin. ... | 05/04/2010 |
| 7687461 | Treatment of TNF-α related disorders with TNF-α variant proteins The invention relates to novel proteins with TNF-alpha antagonist activity and nucleic acids encoding these proteins. The invention further relates to the use of the novel proteins in the treatment of TNF-alpha related disorders. ... | 03/30/2010 |
| 7678886 | Pharmaceutical compositions of adiponectin variants and methods of storage A composition comprising an adiponectin variant at a concentration of at least 2.0 mg/mL, and a pharmaceutically acceptable carrier, wherein less than 20% of said adiponectin variant would aggregate after storage at 4° C. for one week in 10 mM PO4, 150 m... | 03/16/2010 |
| 7662925 | Optimized Fc variants and methods for their generation The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants. ... | 02/16/2010 |
| 7662367 | Pharmaceutical compositions for the treatment of TNF-α related disorders The invention relates to a pharmaceutical composition comprising a variant TNF-α protein that inhibits the activity of soluble TNF-α while substantially maintaining the activity of transmembrane TNF-α a buffer and a tonicity agent wherein said composition has a p... | 02/16/2010 |
| 7657380 | Methods of generating variant antibodies with increased host string content The present invention relates to novel methods for generating variant proteins with increased host string content by comparing a parent protein sequence with two or more natural protein sequences from a host species, analyzing one or more amino acid strings of the p... | 02/02/2010 |
| 7642340 | PEGylated TNF-α variant proteins The present invention relates to the use of simulation technology to rationally optimize the locations and sizes of attached polymeric moieties for modification of therapeutic proteins and the proteins generated from this method. ... | 01/05/2010 |
| 7610156 | Methods for rational pegylation of proteins The present invention relates to the use of simulation technology to rationally optimize the locations and sizes of attached polymeric moieties for modification of therapeutic proteins and the proteins generated from this method. ... | 10/27/2009 |
| 7592423 | Globular adiponectin variants An adiponectin variant with one or more amino acid modifications relative to a corresponding parent adiponectin, wherein the adiponectin variant is not glycosylated, the adiponectin variant does not have residues 1-100 relative to human adiponectin, and wherein the ... | 09/22/2009 |
| 7587286 | Methods for rational pegylation of proteins The present invention relates to the use of simulation technology to rationally optimize the locations and sizes of attached polymeric moieties for modification of therapeutic proteins and the proteins generated from this method. ... | 09/08/2009 |
| 7557190 | Optimized proteins that target Ep-CAM Humanized Ep-CAM-targeting antibodies and methods of making and using the same are provided. ... | 07/07/2009 |
| 7553930 | BAFF variants and methods thereof The invention relates to novel proteins with BAFF dominant negative antagonist, receptor antagonist activity and agonist activity and nucleic acids encoding these proteins. The invention further relates to the use of the novel proteins in the treatment of BAFF or AP... | 06/30/2009 |
| 7459527 | BMP-7 variants with improved properties The invention relates to variants of BMP-7 with improved properties and methods for their use. ... | 12/02/2008 |
| 7446174 | Protein based TNF-α variants for the treatment of TNF-α related disorders The invention relates to novel proteins with TNF-α antagonist activity and nucleic acids encoding these proteins. The invention further relates to the use of the novel proteins in the treatment of TNF-α related disorders. ... | 11/04/2008 |
| 7399829 | Variants of RANKL protein The present invention relates to novel, soluble, recombinant variants RANKL (Receptor Activator of Nuclear Factor—κB Ligand) proteins, which may be expressed solubly in E. coli, variants that act as RANKL antagonists, and methods for generating the same. | 07/15/2008 |
| 7381792 | Variants of RANKL protein The present invention relates to novel, soluble, recombinant RANKL (Receptor Activator of Nuclear Factor—κB Ligand) variant proteins which may be expressed solubly in E. coli, variants that have substantially reduced binding to OPG, variants that act as RA... | 06/03/2008 |
| 7317091 | Optimized Fc variants The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants. ... | 01/08/2008 |
| 7276585 | Immunoglobulin variants outside the Fc region The present invention relates to antibody variants outside the Fc region that alter binding affinity to one or more effector ligands, methods for their generation, and their therapeutic application. ... | 10/02/2007 |
| 7208473 | Nucleic acids and protein variants of hG-CSF with granulopoietic activity The invention relates to novel granulopoietic activity (GPA) proteins and nucleic acids. The invention further relates to the use of the GPA proteins in the treatment of G-CSF related disorders. ... | 04/24/2007 |
| 7071307 | Nucleic acids and proteins with thioredoxin reductase activity The present invention relates to the use of a variety of methods for generating functional thioredoxin reductase variants in which at least one physical, chemical or biological property of the variant is altered in a specific and desired manner when compared to the ... | 07/04/2006 |
| 6946265 | Nucleic acids and proteins with growth hormone activity The invention relates to novel growth hormone activity (GHA) proteins and nucleic acids. The invention further relates to the use of the GHA proteins in the treatment of growth hormone related disorders. ... | 09/20/2005 |
| 6746853 | Proteins with insulin-like activity useful in the treatment of diabetes The invention relates to novel insulin activity (IA) proteins and nucleic acids. The Invention further relates to the use of the IA proteins in the treatment of insulin related disorders such as type 1 diabetes and type 2 diabetes. ... | 06/08/2004 |
| 6514729 | Recombinant interferon-beta muteins The invention relates to novel interferon-beta activity (IbA) proteins and nucleic acids. The invention further relates to the use of the IbA proteins in the treatment of IFN-ଲ related disorders.... | 02/04/2003 |
